Medical Benefit Medication Utilization Policy — sebelipase alfa (LAL deficiency) coverage criteria
Customize your policy alerts
Sign up for all Community-Care policy alerts
Know when Community-Care releases new policies or updates existing guidance.
Monitor payer policy activity
This policy defines medical benefit coverage criteria, authorization, quantity limits, and coding for sebelipase alfa for treatment of lysosomal acid lipase (LAL) deficiency for members under the payer's medical benefit.
No material clinical or coverage changes in this revision.
Coverage Criteria for Sebelipase Alfa
Initial Therapy
Covered when ALL of the following are met:
Continuation Therapy
Covered when ALL of the following are met:
The policy document does not list any explicit exclusions for coverage of sebelipase alfa for treatment of lysosomal acid lipase (LAL) deficiency. No specific patient populations, indications, or circumstances were identified in the source as excluded from consideration.
The policy does not specify any conditions that are explicitly deemed not medically necessary. Coverage determinations are governed by the stated initial and continuation criteria rather than by a named list of noncovered clinical scenarios.
Coding and Authorization Period
| J2840 | Injection, sebelipase alfa, 1 mg |
Provider Requirements and Authorization
Prior Authorization Required
Prior authorization is required. Requests must include documentation confirming the diagnosis of lysosomal acid lipase (LAL) deficiency (see documentation requirements) and confirm the prescriber is an endocrinologist, genetic specialist, or provider specialized in metabolic disorders, or that such a specialist was consulted.
- Prior authorization required for initiation and continuation of therapy
- Prescriber specialty or documented consultation required
Required Documentation
Documentation must include confirmation of LAL enzyme deficiency by enzyme activity testing or genetic testing, clinical presentation details (including age at presentation and disease course), baseline laboratory values (lipid panel, ALT, AST), and patient weight.
- Confirmatory testing: deficient LAL enzyme activity OR pathogenic variant on genetic testing
- Baseline labs: total cholesterol, LDL-C, HDL-C, triglycerides, ALT, AST
- Weight (required for dosing/approval)
Step Therapy
There are no step therapy requirements specified for this therapy.
Triggers for Denial
Coverage may be denied if required documentation is missing or does not confirm LAL deficiency. Examples of triggers for denial include absence of confirmatory enzyme activity or genetic test results, missing prescriber specialty/consultation documentation, lack of baseline laboratory or weight data, or failure to demonstrate initial eligibility criteria.
- Missing confirmatory testing for LAL deficiency
- No documentation of prescriber specialty or specialist consultation
- Absent baseline labs or weight
- Failure to meet initial coverage criteria (e.g., insufficient clinical information on disease presentation)
Background
Lysosomal acid lipase (LAL) deficiency is described in the policy context as a genetic metabolic disorder that requires confirmation by laboratory testing. A diagnosis for coverage purposes must be documented by either deficient LAL enzyme activity or genetic testing demonstrating LAL deficiency. Treatment with sebelipase alfa is managed under specialist care and continuation of therapy is assessed by objective clinical response measures such as changes in lipid levels, liver enzymes, or growth parameters.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.